Zev Wainberg
Overview
Explore the profile of Zev Wainberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
712
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jeong H, Kim B, Lee C, Park I, Zang D, Choi H, et al.
Eur J Cancer
. 2024 Jul;
208:114194.
PMID: 38968872
Introduction: This multicenter phase I/IIa study aimed to determine the recommended phase II dose (RP2D) and evaluate the safety and preliminary efficacy of liposomal irinotecan (nal-IRI), oxaliplatin, and S-1 (NASOX)...
2.
Kitagawa Y, Matsuda S, Gotoda T, Kato K, Wijnhoven B, Lordick F, et al.
Gastric Cancer
. 2024 Feb;
27(3):401-425.
PMID: 38386238
No abstract available.
3.
Shimizu T, Maeda S, Link J, Deranteriassian A, Premji A, Verma A, et al.
Surgery
. 2024 Feb;
175(5):1377-1385.
PMID: 38365548
Background: Neoadjuvant therapy is being increasingly used for patients with pancreatic cancer. The role of adjuvant therapy in these patients is unclear. The purpose of this study was to identify...
4.
Garralda E, Oh D, Italiano A, Bedard P, Delord J, Calvo E, et al.
J Clin Pharmacol
. 2023 Dec;
64(5):544-554.
PMID: 38105505
Tiragolumab is a first-in-class, fully human IgG1/kappa anti-TIGIT monoclonal antibody that blocks the binding of TIGIT to CD155 (the poliovirus receptor). We summarize the pharmacokinetics (PK) data from the phase ...
5.
Kim T, Bedard P, LoRusso P, Gordon M, Bendell J, Oh D, et al.
JAMA Oncol
. 2023 Sep;
9(11):1574-1582.
PMID: 37768658
Importance: Inhibition of the T-cell immunoreceptor with Ig and ITIM domains (TIGIT)/poliovirus receptor pathway may amplify the antitumor immune response of atezolizumab in programmed death ligand 1-selected tumors. Objective: To...
6.
Yoshino T, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, et al.
Nat Commun
. 2023 Jun;
14(1):3332.
PMID: 37286557
DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC) that progressed after ≥2...
7.
Nimgaonkar V, Krishna V, Krishna V, Tiu E, Joshi A, Vrabac D, et al.
Cell Rep Med
. 2023 Apr;
4(4):101013.
PMID: 37044094
Pancreatic ductal adenocarcinoma (PDAC) has been left behind in the evolution of personalized medicine. Predictive markers of response to therapy are lacking in PDAC despite various histological and transcriptional classification...
8.
Epistola R, Sperandio R, Wainberg Z, Iqbal S, Chao J
Cancer Manag Res
. 2023 Mar;
15:265-275.
PMID: 36969544
Esophagogastric cancers are aggressive malignancies, with poor prognosis despite current standard-of-care therapies. PD-1 inhibitors are a newer class of antitumor agents with the potential to improve outcomes among appropriately selected...
9.
Shah M, Kennedy E, Alarcon-Rozas A, Alcindor T, Bartley A, Malowany A, et al.
J Clin Oncol
. 2023 Jan;
41(7):1470-1491.
PMID: 36603169
Purpose: To develop recommendations involving targeted therapies for patients with advanced gastroesophageal cancer. Methods: The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of...
10.
Janjigian Y, Van Cutsem E, Muro K, Wainberg Z, Al-Batran S, Hyung W, et al.
Future Oncol
. 2022 May;
18(20):2465-2473.
PMID: 35535555
Standard-of-care for resectable gastric/gastroesophageal junction cancer includes surgery and neoadjuvant-adjuvant 5-fluorouracil-leucovorin-oxaliplatin-docetaxel (FLOT) chemotherapy. Early-phase clinical studies support further clinical development of the immune checkpoint inhibitor (ICI); durvalumab, an anti-PD-L1 antibody,...